{"id":"NCT01272232","sponsor":"Novo Nordisk A/S","briefTitle":"Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes","officialTitle":"Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06-01","primaryCompletion":"2013-01-01","completion":"2013-01-25","firstPosted":"2011-01-07","resultsPosted":"2015-02-09","lastUpdate":"2017-12-29"},"enrollment":846,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metabolism and Nutrition Disorder","Obesity"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Lira 3.0 mg","type":"EXPERIMENTAL"},{"label":"Lira 1.8 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in Africa, Asia, Europe and the United States of America (USA).\n\nThe aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with type 2 diabetes. Treatment will be added onto subject's pre-trial background diabetes treatment of either diet and exercise only or single compound oral antidiabetic drug (OAD) treatment (metformin, sulphonylurea \\[SU\\] or glitazone) or combination OAD treatment (metformin, sulphonylurea or glitazone). The duration of the trial will be 56 weeks followed by a 12 week observational follow-up period.","primaryOutcome":{"measure":"Change (%) From Baseline in Body Weight (Fasting)","timeFrame":"Week 0, week 56","effectByArm":[{"arm":"Liraglutide 3.0 mg","deltaMin":-5.9,"sd":5.5},{"arm":"Liraglutide 1.8 mg","deltaMin":-4.6,"sd":5.5},{"arm":"Liraglutide Placebo","deltaMin":-2,"sd":4.3}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"0.0024"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":161,"countries":["United States","France","Germany","India","Israel","Italy","Puerto Rico","South Africa","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["29145215","27193270","27482610","27804269","27817208","26744025","26833744","26284720","26418188","28473337","28462892","28386912","28950422"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":422},"commonTop":["Hypoglycaemia","Nausea","Diarrhoea","Nasopharyngitis","Headache"]}}